EFFETTI A MEDIO E LUNGO TERMINE DI DIVERSI SCHEMI DI TRATTAMENTO CON S-CALCITONINA SPRAY NASALE

Translated title of the contribution: Calcitonin nasal spray in osteoporosis: Short and long-term effects of various treatment regimes

M. Maini, M. Bozzi, E. Brignoli, G. Felicetti

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

188 patients with high-turnover type postmenopausal osteoporosis were treated for 18 months with 4 different treatment regimens of S-calcitonin nasal spray. For a total of 18 months group 1 was given 100 IU/day, continuously; group 2, 100 IU/day daily for 30 days every other month ('cyclically'); group 3, 200 IU/day continuously, and group 4, 200 IU/day, cyclically. To monitor the effects of treatment, MOC of L2-L4, as well as serum osteocalcin and urinary hydroxyproline: creatinine levels were measured, on initiation of therapy, then at 9, 12 and 18 months, and finally at 6 and 12 months after completion of therapy. Analysis of the results yields the following major points: (A) The peak increase in bone mass occurs at 9 months the continuous therapy groups, and at 18 months in the cyclic therapy groups. In absolute values, the peak are higher in the continuous groups than in the cyclic groups. (B) The long-term increase in bone mass (measured at one year after completion of therapy) does not differ significantly between cyclic and continuous treatment groups at the same dosage. (C) During treatment, a dose-effect relationship exist when comparing dosages of 100 IU/day and 200 IU/day. However, this disappears by one year after completion of therapy. (D) There seems to be a 'rebound effect' on osseous turnover after cessation of S-calcitonin therapy. The magnitude and rapidity of onset of this effect appear to correlate directly with the dosage of S-calcitonin administered.

Original languageItalian
Pages (from-to)121-127
Number of pages7
JournalMinerva Medica
Volume86
Issue number3
Publication statusPublished - 1995

Fingerprint

Nasal Sprays
Calcitonin
Osteoporosis
Therapeutics
Group Psychotherapy
Bone and Bones
Postmenopausal Osteoporosis
Hydroxyproline
Osteocalcin
Creatinine

ASJC Scopus subject areas

  • Medicine(all)

Cite this

EFFETTI A MEDIO E LUNGO TERMINE DI DIVERSI SCHEMI DI TRATTAMENTO CON S-CALCITONINA SPRAY NASALE. / Maini, M.; Bozzi, M.; Brignoli, E.; Felicetti, G.

In: Minerva Medica, Vol. 86, No. 3, 1995, p. 121-127.

Research output: Contribution to journalArticle

@article{8e69ce24b4ab4ba9b53b5bc40a11ab82,
title = "EFFETTI A MEDIO E LUNGO TERMINE DI DIVERSI SCHEMI DI TRATTAMENTO CON S-CALCITONINA SPRAY NASALE",
abstract = "188 patients with high-turnover type postmenopausal osteoporosis were treated for 18 months with 4 different treatment regimens of S-calcitonin nasal spray. For a total of 18 months group 1 was given 100 IU/day, continuously; group 2, 100 IU/day daily for 30 days every other month ('cyclically'); group 3, 200 IU/day continuously, and group 4, 200 IU/day, cyclically. To monitor the effects of treatment, MOC of L2-L4, as well as serum osteocalcin and urinary hydroxyproline: creatinine levels were measured, on initiation of therapy, then at 9, 12 and 18 months, and finally at 6 and 12 months after completion of therapy. Analysis of the results yields the following major points: (A) The peak increase in bone mass occurs at 9 months the continuous therapy groups, and at 18 months in the cyclic therapy groups. In absolute values, the peak are higher in the continuous groups than in the cyclic groups. (B) The long-term increase in bone mass (measured at one year after completion of therapy) does not differ significantly between cyclic and continuous treatment groups at the same dosage. (C) During treatment, a dose-effect relationship exist when comparing dosages of 100 IU/day and 200 IU/day. However, this disappears by one year after completion of therapy. (D) There seems to be a 'rebound effect' on osseous turnover after cessation of S-calcitonin therapy. The magnitude and rapidity of onset of this effect appear to correlate directly with the dosage of S-calcitonin administered.",
keywords = "calcitonin, disability, osteoporosis",
author = "M. Maini and M. Bozzi and E. Brignoli and G. Felicetti",
year = "1995",
language = "Italian",
volume = "86",
pages = "121--127",
journal = "Minerva Medicolegale e Archivio di Antropologia Criminale",
issn = "0026-4806",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "3",

}

TY - JOUR

T1 - EFFETTI A MEDIO E LUNGO TERMINE DI DIVERSI SCHEMI DI TRATTAMENTO CON S-CALCITONINA SPRAY NASALE

AU - Maini, M.

AU - Bozzi, M.

AU - Brignoli, E.

AU - Felicetti, G.

PY - 1995

Y1 - 1995

N2 - 188 patients with high-turnover type postmenopausal osteoporosis were treated for 18 months with 4 different treatment regimens of S-calcitonin nasal spray. For a total of 18 months group 1 was given 100 IU/day, continuously; group 2, 100 IU/day daily for 30 days every other month ('cyclically'); group 3, 200 IU/day continuously, and group 4, 200 IU/day, cyclically. To monitor the effects of treatment, MOC of L2-L4, as well as serum osteocalcin and urinary hydroxyproline: creatinine levels were measured, on initiation of therapy, then at 9, 12 and 18 months, and finally at 6 and 12 months after completion of therapy. Analysis of the results yields the following major points: (A) The peak increase in bone mass occurs at 9 months the continuous therapy groups, and at 18 months in the cyclic therapy groups. In absolute values, the peak are higher in the continuous groups than in the cyclic groups. (B) The long-term increase in bone mass (measured at one year after completion of therapy) does not differ significantly between cyclic and continuous treatment groups at the same dosage. (C) During treatment, a dose-effect relationship exist when comparing dosages of 100 IU/day and 200 IU/day. However, this disappears by one year after completion of therapy. (D) There seems to be a 'rebound effect' on osseous turnover after cessation of S-calcitonin therapy. The magnitude and rapidity of onset of this effect appear to correlate directly with the dosage of S-calcitonin administered.

AB - 188 patients with high-turnover type postmenopausal osteoporosis were treated for 18 months with 4 different treatment regimens of S-calcitonin nasal spray. For a total of 18 months group 1 was given 100 IU/day, continuously; group 2, 100 IU/day daily for 30 days every other month ('cyclically'); group 3, 200 IU/day continuously, and group 4, 200 IU/day, cyclically. To monitor the effects of treatment, MOC of L2-L4, as well as serum osteocalcin and urinary hydroxyproline: creatinine levels were measured, on initiation of therapy, then at 9, 12 and 18 months, and finally at 6 and 12 months after completion of therapy. Analysis of the results yields the following major points: (A) The peak increase in bone mass occurs at 9 months the continuous therapy groups, and at 18 months in the cyclic therapy groups. In absolute values, the peak are higher in the continuous groups than in the cyclic groups. (B) The long-term increase in bone mass (measured at one year after completion of therapy) does not differ significantly between cyclic and continuous treatment groups at the same dosage. (C) During treatment, a dose-effect relationship exist when comparing dosages of 100 IU/day and 200 IU/day. However, this disappears by one year after completion of therapy. (D) There seems to be a 'rebound effect' on osseous turnover after cessation of S-calcitonin therapy. The magnitude and rapidity of onset of this effect appear to correlate directly with the dosage of S-calcitonin administered.

KW - calcitonin

KW - disability

KW - osteoporosis

UR - http://www.scopus.com/inward/record.url?scp=0029036506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029036506&partnerID=8YFLogxK

M3 - Articolo

C2 - 7603607

AN - SCOPUS:0029036506

VL - 86

SP - 121

EP - 127

JO - Minerva Medicolegale e Archivio di Antropologia Criminale

JF - Minerva Medicolegale e Archivio di Antropologia Criminale

SN - 0026-4806

IS - 3

ER -